Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday

Cassava Sciences (NASDAQ:SAVA) is scheduled to be releasing its earnings data before the market opens on Thursday, November 7th. Analysts expect Cassava Sciences to post earnings of ($1.37) per share for the quarter.

Cassava Sciences (NASDAQ:SAVA) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.57. During the same quarter in the prior year, the company posted ($0.63) EPS. On average, analysts expect Cassava Sciences to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cassava Sciences Stock Performance

Cassava Sciences stock opened at $26.35 on Friday. Cassava Sciences has a one year low of $8.79 and a one year high of $42.20. The stock has a fifty day moving average of $28.09 and a 200 day moving average of $22.79. The stock has a market cap of $1.26 billion, a PE ratio of -18.30 and a beta of -0.63.

Analysts Set New Price Targets

Several research firms have recently commented on SAVA. HC Wainwright raised Cassava Sciences from a “neutral” rating to a “buy” rating and set a $116.00 price objective on the stock in a research note on Tuesday, October 8th. Rodman & Renshaw restated a “buy” rating and set a $107.00 price objective on shares of Cassava Sciences in a research report on Thursday, August 8th.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.